Fingerprint
Dive into the research topics of 'First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee, Sarah Cooley, Melissa M. Berrien-Elliott, Peter Westervelt, Michael R. Verneris, John E. Wagner, Daniel J. Weisdorf, Bruce R. Blazar, Celalettin Ustun, Todd E. DeFor, Sithara Vivek, Lindsey Peck, John F. DiPersio, Amanda F. Cashen, Rachel Kyllo, Amy Musiek, András Schaffer, Milan J. Anadkat, Ilana Rosman, Daniel Miller
- Institute of Clinical and Translational Sciences
- Siteman Cancer Center
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Human Research Protection Office (HRPO)
- Division of Dermatology
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Section of Bone Marrow Transplant & Leukemia
- Section of Stem Cell Biology
- Division of Oncology
- Institute for Public Health
- Center of Regenerative Medicine
- DBBS - Immunology
- DBBS - Cancer Biology
Research output: Contribution to journal › Article › peer-review
240
Scopus
citations